Biofrontera AG is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies in dermatology. Established in 1997 and headquartered in Leverkusen, Germany, the company concentrates its efforts on photodynamic therapy (PDT) for the treatment of actinic keratosis and other skin conditions. Biofrontera’s core technology revolves around the use of aminolevulinic acid (ALA) formulations that selectively target abnormal cells, offering a non-invasive alternative to traditional surgical procedures.
The company’s flagship product, Ameluz, is an ALA-based gel approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for lesion-directed PDT. To complement Ameluz, Biofrontera markets proprietary light-emitting devices, including the BF-RhodoLED® lamp in Europe and the BLU-U® system in the United States, designed to activate the photosensitizer and enhance therapeutic outcomes. These products are supported by clinical data demonstrating efficacy and safety in the treatment of actinic keratosis and basal cell carcinoma lesions.
Biofrontera serves a global customer base through its European operations and a subsidiary in the United States, Biofrontera Inc., located in Wilmington, Delaware. The company has forged strategic partnerships and licensing agreements to strengthen its market presence, including collaborations for distribution in Canada, Latin America, and parts of Asia. Continued engagement with regulatory authorities underscores Biofrontera’s commitment to expanding its product approvals and securing reimbursement pathways in key markets.
Under the leadership of Chief Executive Officer Dr. Andreas Wolf and Chief Financial Officer Daniel Otto, Biofrontera pursues a growth strategy centered on pipeline diversification and international expansion. The management team combines scientific expertise with commercial acumen, aiming to introduce next-generation PDT solutions and to explore new dermatological indications. The company maintains active R&D programs and seeks collaboration opportunities to bolster its long-term position in the dermatology segment.
AI Generated. May Contain Errors.